SABS
SAB Biotherapeutics, Inc.
Biotechnology
Market Cap$181M
5Y Perf.-95.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SABS vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+72.5%
SABS vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SABS | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $181M | $5.83B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $13M | $-464M |
| Total Debt | $6M | $98K |
| Cash & Equiv. | $11M | $714M |
SABS vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SABS
IMVT
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| SAB Biotherapeutics… (SABS) | 100 | 4.1 | -95.9% |
| Immunovant, Inc. (IMVT) | 100 | 172.5 | +72.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SABS vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SABS leads in 3 of 5 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Immunovant, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
SABS
SAB Biotherapeutics, Inc.
The Income Pick
SABS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.80
- Rev growth -100.0%, EPS growth 78.5%
- Lower volatility, beta 0.80, Low D/E 3.9%, current ratio 9.46x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 188.1% 10Y total return vs SABS's -96.3%
- -21.3% revenue growth vs SABS's -100.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs SABS's -100.0% |
| Stability / Safety | SABS | Beta 0.80 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SABS | +127.5% vs IMVT's +107.2% |
| Efficiency (ROA) | SABS | 12.5% ROA vs IMVT's -44.1% |
SABS vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
SABS vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSABSLAGGINGIMVT
IMVTImmunovant, Inc.
1leads
SABSSAB Biotherapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SABS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SABS4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SABS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SABS and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SABSSAB Biotherapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$47M | -$487M |
| Net IncomeAfter-tax profit | $13M | -$464M |
| Free Cash FlowCash after capex | -$45M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +187.0% | +19.7% |
SABS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SABS and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SABSSAB Biotherapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $181M | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $176M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -4.81x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.54x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SABS and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SABS leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
SABS delivers a 15.2% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SABS's 0.04x. On the Piotroski fundamental quality scale (0–9), SABS scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | SABSSAB Biotherapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +15.2% | -47.1% |
| ROA (TTM)Return on assets | +12.5% | -44.1% |
| ROICReturn on invested capital | -43.5% | — |
| ROCEReturn on capital employed | -49.4% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.04x | 0.00x |
| Net DebtTotal debt minus cash | -$5M | -$714M |
| Cash & Equiv.Liquid assets | $11M | $714M |
| Total DebtShort + long-term debt | $6M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | 266.50x | — |
SABS leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $383 for SABS. Over the past 12 months, SABS leads with a +127.5% total return vs IMVT's +107.2%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs SABS's -27.1% — a key indicator of consistent wealth creation.
| Metric | SABSSAB Biotherapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +0.8% | +10.7% |
| 1-Year ReturnPast 12 months | +127.5% | +107.2% |
| 3-Year ReturnCumulative with dividends | -61.2% | +48.4% |
| 5-Year ReturnCumulative with dividends | -96.2% | +73.9% |
| 10-Year ReturnCumulative with dividends | -96.3% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -27.1% | +14.1% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SABS and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
SABS is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 95.3% from its 52-week high vs SABS's 57.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SABSSAB Biotherapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.80x | 1.37x |
| 52-Week HighHighest price in past year | $6.60 | $30.09 |
| 52-Week LowLowest price in past year | $1.60 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +57.6% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 47.9 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 594K | 1.4M |
Evenly matched — SABS and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SABS as "Buy" and IMVT as "Buy". Consensus price targets imply 84.2% upside for SABS (target: $7) vs 58.7% for IMVT (target: $46).
| Metric | SABSSAB Biotherapeuti… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $45.50 |
| # AnalystsCovering analysts | 6 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SABS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IMVT leads in 1 (Total Returns). 2 tied.
Best OverallSAB Biotherapeutics, Inc. (SABS)Leads 2 of 6 categories
Loading custom metrics...
SABS vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SABS or IMVT a better buy right now?
Analysts rate SAB Biotherapeutics, Inc.
(SABS) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SABS or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -96. 2% for SAB Biotherapeutics, Inc. (SABS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SABS's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SABS or IMVT?
By beta (market sensitivity over 5 years), SAB Biotherapeutics, Inc.
(SABS) is the lower-risk stock at 0. 80β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 72% more volatile than SABS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 4% for SAB Biotherapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SABS or IMVT?
On earnings-per-share growth, the picture is similar: SAB Biotherapeutics, Inc.
grew EPS 78. 5% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SABS or IMVT?
SAB Biotherapeutics, Inc.
(SABS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SABS leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — SABS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SABS or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SABS or IMVT better for a retirement portfolio?
For long-horizon retirement investors, SAB Biotherapeutics, Inc.
(SABS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80)). Both have compounded well over 10 years (SABS: -96. 0%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SABS and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.